FENC

Business Context and Reporting Period

Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 6-K (Interim Financial Statements)
Reporting Period: Three months ended September 30, 2004 (First Quarter of Fiscal 2005)
Business Stage: Development-stage biopharmaceutical company focused on cancer therapeutics and a cadherin-based tumor vascular targeting platform.
Key Activities: The company has no commercial revenue. Operations focus on clinical trials for four product candidates: Exherin (vascular targeting), Sodium Thiosulfate (chemoprotectant), N-Acetylcysteine (chemoprotectant), and Mesna (chemoenhancer).

Key Financial Metrics

Note: All figures are in Canadian dollars (CAD) in thousands, unless otherwise noted.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately 69% (from $2.1 million to $3.6 million) compared to the same period in 2003. This was driven by higher operating expenses.
• Operating Expenses: Total operating expenses rose 80% to $4.0 million.
  • R&D Expenses: Increased from $0.8 million to $1.6 million, primarily due to expanded clinical activities for Exherin and increased headcount in Research Triangle Park (RTP).
  • G&A Expenses: Increased from $0.6 million to $1.6 million, driven by the establishment of U.S. offices in RTP and recruitment costs.
• Liquidity Position: Cash and cash equivalents decreased from $18.2 million (June 30, 2004) to $15.3 million (September 30, 2004) due to operational spending. However, total liquidity (including short-term investments) remains strong at approximately $24.8 million.
• Accounting Policy Change: The company adopted CICA 3870 regarding stock-based compensation. Effective July 1, 2004, the company retroactively adjusted accumulated deficit by $2.1 million to expense the fair value of employee options.

Guidance, Outlook, and Risks

• Outlook: Management expects R&D and G&A expenses to increase in future quarters as clinical programs expand. The company believes current cash resources are sufficient to fund operations for at least the next 18 months.
• Capital Needs: The company will require substantial additional funding through equity, debt, or collaborations to continue development and commercialization. There is no assurance such funding will be available on favorable terms.
• Clinical Progress: Phase I trials for Exherin have shown evidence of anti-tumor activity and were generally well tolerated. A Phase III trial for Sodium Thiosulfate (STS) in children is anticipated to start in 2005.
• Legal Contingency (Cadherin Biomedical Inc. - CBI):
  • Adherex filed a claim against CBI for $124,000; CBI counterclaimed for $5.0 million.
  • A letter of intent was signed in July 2004 to acquire CBI via amalgamation, valued at approximately $1.5 million in shares. This transaction is expected to settle the legal disputes.
  • Closing is subject to shareholder approval and is expected in November or December 2004.
• Contractual Obligations: Total contractual obligations (leases and license fees) are approximately $3.3 million over the next 5+ years. A potential $0.5 million milestone payment to OHSU is contingent on completing a Phase III STS trial.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $24.8 million liquidity position against the projected 18-month runway given the accelerating R&D spend.
• CBI Transaction Status: Confirm the closing of the Cadherin Biomedical Inc. amalgamation to resolve the $5 million counterclaim risk.
• Exherin Clinical Data: Review detailed Phase I clinical trial results to validate the "evidence of anti-tumor activity" cited in the press release.
• Accounting Adjustments: Understand the full impact of the CICA 3870 stock-based compensation adoption on future quarterly earnings.
• Regulatory Milestones: Monitor the timeline for the anticipated Phase III STS trial in 2005 and associated milestone payment obligations.